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Intracellular oligomeric  
amyloid-beta rapidly regulates 
GluA1 subunit of AMPA receptor in 
the hippocampus
Daniel J. Whitcomb1,2,*, Ellen L. Hogg1,2,*, Philip Regan1,2,3, Thomas Piers1,2, 
Priyanka Narayan4, Garry Whitehead1,2, Bryony L. Winters1,2,3, Dong-Hyun Kim1, 
Eunjoon Kim5, Peter St George-Hyslop6, David Klenerman4, Graham L. Collingridge1,2,3, 
Jihoon Jo1 & Kwangwook Cho1,2
The acute neurotoxicity of oligomeric forms of amyloid-β 1-42 (Aβ ) is implicated in the pathogenesis 
of Alzheimer’s disease (AD). However, how these oligomers might first impair neuronal function at the 
onset of pathology is poorly understood. Here we have examined the underlying toxic effects caused 
by an increase in levels of intracellular Aβ , an event that could be important during the early stages of 
the disease. We show that oligomerised Aβ induces a rapid enhancement of AMPA receptor-mediated 
synaptic transmission (EPSCA) when applied intracellularly. This effect is dependent on postsynaptic 
Ca2+ and PKA. Knockdown of GluA1, but not GluA2, prevents the effect, as does expression of a S845-
phosphomutant of GluA1. Significantly, an inhibitor of Ca2+-permeable AMPARs (CP-AMPARs), IEM 
1460, reverses the increase in the amplitude of EPSCA. These results suggest that a primary neuronal 
response to intracellular Aβ oligomers is the rapid synaptic insertion of CP-AMPARs.
Alzheimer’s disease (AD) is defined by two hallmark pathological features: plaques that are composed of 
insoluble conjugates of the amyloid precursor protein (APP) cleavage product amyloid beta1-42 (Aβ ), 
and tangles, which are mainly composed of hyperphosphorylated tau1. A large number of studies have 
now established that Aβ causes neurotoxic effects at the synapse, including the dysregulation of synaptic 
proteins and degeneration of dendritic spines1,2. However, the cellular events that lead to these patholog-
ical changes are poorly characterised, which both limits our understanding of the disease and potentially 
hampers the development of efficacious therapies.
One approach that has been extensively utilised to probe the mechanism of Aβ toxicity is to apply 
oligomeric forms of the protein acutely to the hippocampus, and study their effects on synaptic trans-
mission and plasticity3–6. Here, Aβ is applied extracellularly, either by injection into the brain or by the 
perfusion of hippocampal slices, and its toxic effects can take an hour or more to manifest4,5. However, 
it is unknown whether these noted toxic effects are preceded by other as yet undefined extracellular and 
intracellular responses to Aβ exposure.
1Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology (LINE). 2Centre for Synaptic 
Plasticity, Faculty of Medicine and Dentistry, University of Bristol, Whitson Street, Bristol BS1 3NY, United 
Kingdom. 3School of Physiology and Pharmacology, University of Bristol, Bristol BS8 1TD, United Kingdom. 
4Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, UK. 5Center for Synaptic Brain 
Dysfunctions, Institute for Basic Science and Department of Biological Sciences, Korea Advanced Institute of 
Science and Technology, Daejeon 305-701, South Korea. 6Department of Clinical Neurosciences, Cambridge 
Institute for Medical Research, University of Cambridge, Cambridge, UK. *These author contributed equally to 
this work. Correspondence and requests for materials should be addressed to K.C. (email: Kei.Cho@bristol.ac.uk)
Received: 17 February 2015
Accepted: 08 May 2015
Published: 09 June 2015
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 5:10934 | DOi: 10.1038/srep10934
Given the extracellular nature of Aβ exposure in these experiments, it is assumed that the toxic 
effects observed are mediated by a membrane-bound substrate or event, and/or by the internalization of 
Aβ by affected neurons. Indeed, evidence suggests that plasma membrane receptors serve as substrates 
for oligomeric Aβ 7. For instance, both metabotropic glutamate receptors and the prion protein receptor 
interact with Aβ at the synapse, and these interactions are known to catalyse synaptic dysfunction and 
cell death8–13. In addition to this, studies now report the capacity for Aβ to form pores in the lipid bilayers 
of membranes14–17, which can serve as conduits to induce the aberrant entry of Ca2+ into cells. However, 
there is some uncertainty about the conditions in which membrane receptors and associated events are 
responsible for the toxic effects18–20, suggesting that additional mechanisms likely also play a role.
A growing number of studies now describe an emerging role of intracellular Aβ accumulation in the 
pathology of AD21,22. For instance, misprocessed endogenously produced Aβ can accumulate in intracel-
lular compartments as well as the cytosol itself21. Several lines of evidence also suggest that extracellular 
Aβ can translocate into the cytosol from extracellular spaces23–25. Critically, it has been shown that the 
internalization of Aβ and the presumed increase in the presence of Aβ in intracellular spaces can induce 
synaptic dysfunction26,27. We have therefore hypothesized that accumulated intracellular Aβ will cause a 
primary effect on neuronal function. To test this, we have applied Aβ acutely into neurons via a patch 
electrode and investigated whether intracellular Aβ regulates excitatory synaptic transmission in the 
CA1-Schaffer collateral synapse in the hippocampus.
Results
Single molecule two-colour fluorescence coincidence detection and analysis of oli-
gomers. Increasing evidence suggests that small, soluble Aβ oligomers are the driving force in 
Aβ -mediated toxicity, and their production leads to synaptic dysfunction3–5. Using a protocol whereby 
synthetic Aβ was aggregated (see Methods), we were able to induce a high population of low-n oligomers, 
quantified using a single-molecule fluorescence method of confocal two-color coincidence detection 
(cTCCD) of fluorescently labeled Aβ (Fig. 1a)28. This protocol generated a heterogeneous preparation of 
Aβ oligomers, which equated to a 1–5 nM component of oligomers (Fig. 1b, c).
Intracellular infusion of oligomerised Aβ1-42 (Aβ) causes a rapid increase in the 
AMPAR-mediated EPSC (EPSCA) in CA1 pyramidal neurons. Since Aβ oligomers are toxic3–5, 
we were interested in determining the intracellular effects of Aβ oligomers on synaptic function. 
Neurons were injected with oligomerised Aβ via passive diffusion from the patch pipette, whilst basal 
synaptic transmission was measured. Aβ oligomers caused a rapid increase in the amplitude of the 
AMPAR-mediated excitatory postsynaptic current (EPSCA) (181 ± 15%, n = 7, Fig. 2a). In contrast, nei-
ther the infusion of non-aggregated, monomeric Aβ nor Aβ oligomers that had been pre-incubated with 
clusterin, a chaperone that sequesters oligomers28, had any significant effect upon EPSCA (81 ± 8%, n = 6, 
Fig.  2b and 103 ± 9%, n = 7, Fig.  2c, respectively). The effect of Aβ oligomers was independent of the 
need to evoke EPSCA, since stopping stimulation for 15 min, shortly after obtaining whole-cell configu-
ration, did not prevent the increase in synaptic transmission (closed circle: 192 ± 26%, n = 6, Fig. 2d). In 
addition, the effect of Aβ oligomers did not require the activation of NMDA receptors (NMDAR), since 
EPSCA was enhanced in the presence of the NMDAR antagonist D-AP-5 (147 ± 14%, n = 6, Fig. 2e). This 
effect was also specific for EPSCA since a pharmacologically-isolated NMDAR-mediated EPSC (EPSCN: 
holding voltage –40 mV, 10 μ M NBQX perfusion) was unaffected by Aβ oligomer infusion (99 ± 14%, 
n = 6, Fig. 2f).
Aβ oligomer-induced increase in EPSCA is dependent on postsynaptic Ca2+ and PKA. We next 
investigated the signalling cascades that underlie the rapid action of Aβ oligomers on AMPAR-mediated 
synaptic transmission (Fig.  3). Changes in postsynaptic Ca2+ levels initiate signal cascades involved in 
the modulation of synaptic transmission29–31. Therefore we tested whether blockade of postsynaptic Ca2+ 
mobilisation affects Aβ -mediated EPSCA regulation. The Aβ oligomer-induced increase was depend-
ent on postsynaptic Ca2+, since it was prevented by postsynaptic infusion of the Ca2+ chelator BAPTA 
(95 ± 12%, n = 7, Fig. 3a), and relied on Ca2+ release from intracellular stores, since bath applied ryan-
odine also prevents the Aβ -induced EPSCA increase (108 ± 18%, n = 7, Fig.  3b). We were interested 
in examining the Ca2+-dependent mechanism responsible for these effects, and possible downstream 
effectors. Ca2+-induced changes in synaptic transmission are known to involve, among other kinases, 
protein kinase A (PKA)32,33. Accordingly, we tested the involvement of PKA in the observed Aβ -induced 
EPSCA increase. We found that the effect required the activation of PKA, since it was prevented by either 
Rp-cAMPS, a cyclic AMP analogue that acts as a competitive antagonist of cAMP-induced activation of 
PKA (97 ± 8%, n = 6, Fig. 3c) or H89, a PKA inhibitor (94 ± 9%, n = 6, Fig. 3d), but not PKC since it 
was unaffected by both the PKC inhibitor Ro 32-0432 (171 ± 7%, n = 6, Fig. 3e) or PKC19-31, a pseudo-
substrate of PKC which functions to inhibit the kinase (166 ± 13%, n = 6, Fig. 3f).
Calcium-calmodulin kinase II (CaMKII) is a Ca2+-sensitive kinase that has also been implicated in 
the regulation of AMPAR expression34,35. We therefore tested the involvement of CaMKII in Aβ -induced 
EPSCA increase. When cells were infused with Aβ and the CaMKII inhibitor KN-62, we observed an 
initial increase in EPSCA that rapidly declined (97 ± 16%, n = 7, Fig. 3g).
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Figure 1. Generation of lower-n oligomers of Aβ1-42 (Aβ) (a) A schematic of the principle of single 
molecule two-colour fluorescence coincidence detection and analysis of oligomers. The protein is labeled 
with a red or blue fluorophore and aggregated. The sample is then diluted to picomolar concentrations and 
analysed using single molecule fluorescence. Monomers passing through the probe volume give rise to non-
coincident bursts of fluorescence while oligomers give rise to coincident fluorescent bursts, enabling the 
fraction of oligomers present in the sample to be determined. The intensity of a coincident burst relative 
to average monomer bursts was determined, allowing the oligomer size to be estimated. (b) Histogram 
depicting the proportion of monomers and oligomers. (c) Histogram depicting the size distribution of 
oligomers present in the preparation of Aβ oligomers.
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Figure 2. Intracellular infusion of Aβ causes a rapid increase in the AMPAR-mediated EPSC (EPSCA). 
(a) The infusion of 1–5 nM oligomeric Aβ into post-synaptic neurons induces a rapid increase in EPSCA 
(n = 7). (b) Monomeric Aβ did not induce an increase in EPSCA (n = 6). (c) Clusterin (500 nM) prevented 
the Aβ oligomer-induced facilitation of EPSCA (n = 6). (d) The increase in EPSCA is independent of synaptic 
activity (n = 6). Filled circles depict Aβ infused neurons and open circles depict control neurons. (e) An 
NMDAR-antagonist, D-AP5 (50 M) has no effect on the Aβ oligomer-induced facilitation of EPSCA (n = 6). 
(f) The NMDAR mediated EPSC (EPSCN) is unaffected by infusion of Aβ oligomers (n = 6). In this (and 
subsequent figures) graphs plot the mean ± S.E.M. of n experiments.
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Figure 3. Aβ oligomer-induced increase in EPSCA is dependent on Ca2+ and PKA. (a) Neurons were 
infused with Aβ oligomer in the presence of BAPTA (10 mM) in the filling solution. This prevented the 
Aβ oligomer facilitated increase in EPSCA (n = 7). (b) Ryanodine infusion via the pipette prevented the Aβ 
facilitated increase in EPSCA (n = 7). (c) There was no increase in EPSCA following preincubation (30 min) 
with RP-cAMPS (100 μ M) (n = 6). (d) H89 infusion via the pipette prevented the Aβ facilitated increase in 
EPSCA (n = 6). (e) Ro 32-0432 (10 μ M) infusion via the pipette had no effect on the Aβ -mediated increase of 
EPSCA (n = 6). (f) PKC 19-31 infusion via the pipette did not prevent the Aβ facilitated increase in EPSCA 
(n = 6). (g) KN-62 (10 μ M) preincubation (45 min) and infusion via the pipette prevented the sustained Aβ 
facilitation of EPSCA (n = 7).
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Figure 4. Aβ oligomer-induces expression of CP-AMPARs (a) Aβ failed to increase EPSCA in GluA1-
shRNA transfected cells (n = 7). (b) Aβ oligomers infusion increases EPSCA in GluA2-shRNA transfected 
cells (n = 8). (c) Aβ failed to increase EPSCA in GluA1-S845 phosphomutant transfected cells (n = 7).  
(d) Bath application of IEM 1460 (100 μ M) has no effect on basal transmission EPSCA (n = 6). (e) The Aβ 
oligomer-mediated increase in EPSCA is reduced by bath application of IEM (n = 8).
Aβ oligomer-induced enhancement of EPSCA is mediated by the GluA1 subunit of 
AMPARs. Since homomeric forms of GluA1-AMPARs characteristically display greater conductance 
than GluA2 containing AMPARs36,37, we hypothesized that infusion of Aβ facilitates EPSCA through an 
increase in synaptic homomeric GluA1 AMPARs. Indeed, the activation of PKA can lead to the insertion 
of GluA1-containing, GluA2-lacking AMPARs, known as Ca2+-permeable AMPARs (CP-AMPARs)38,39. 
To test this, we knocked down either GluA1 or GluA2 in neurons of organotypic hippocampal slices 
using biolistic shRNA transfection. GluA1-shRNA transfected cells did not show the rapid effect of 
Aβ oligomer infusion on EPSCA (90 ± 7%, n = 7, Fig.  4a). In comparison, a rapid increase of EPSCA 
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was observed in GluA2-shRNA transfected cells (176 ± 18%, n = 8, Fig.  4b). The synaptic expression 
of GluA1 involves the PKA-dependent phosphorylation of the serine 845 residue (s845) of GluA140. 
Therefore, we knocked down endogenous GluA1 whilst simultaneously expressing an shRNA resistant 
form of GluA1 that cannot be phosphorylated at s845 (s845-phosphomutant). Infusion of Aβ oligomers 
in s845-phosphomutated cells had no effect on EPSCA (89 ± 8%, n = 7, Fig. 4c).
Collectively, these data suggest that the rapid Aβ oligomer-induced changes in EPSCA may be due 
to a PKA-dependent synaptic insertion of CP-AMPARs. To test this directly, we bath-applied IEM 1460 
(IEM), a compound that selectively blocks CP-AMPARs41. IEM had no effect on EPSCA when using 
control pipette solution (99 ± 8%: 30 min after IEM treatment, n = 6, Fig. 4d), which is consistent with 
a negligible contribution by CP-AMPARs to basal AMPAR-mediated transmission. However, IEM dra-
matically reduced the EPSCA following infusion with Aβ oligomers (159 ± 11%: 10 min after infusion of 
Aβ oligomers; 77 ± 10%: 30 min after the start of IEM treatment, n = 8, Fig. 4e). This suggests that Aβ 
oligomer infusion causes a rapid increase in the synaptic expression of CP-AMPARs, resulting in the 
observed facilitation of EPSCA amplitude.
Using biotinylation assays from hippocampal slices, we found that the surface expression of GluA1 was 
significantly increased with exogenous Aβ treatment but that there was no change in GluA2/3 expression 
(Fig. 5A). This suggests that exogenously applied Aβ also induces the insertion of CP-AMPARs. To sup-
port these findings, we measured EPSCA during the extracellular perfusion of Aβ . We found that there 
was an increase of EPSCA on application of Aβ  (145 ± 7%, n = 6, Fig. 5B), which was prevented when 
slices were continually perfused with IEM (89 ± 6%, n = 6, Fig. 5C).
Discussion
Here we have revealed a rapid synaptic response to intracellular accumulation of Aβ oligomers. Several 
lines of evidence suggest that extracellular Aβ oligomers are taken up into neurons where they impair 
synaptic function22. By studying the effects of intracellularly applied Aβ oligomers we have found a rapid 
action: the insertion of CP-AMPARs via a PKA-dependent phosphorylation of s845 of GluA1. These 
effects, occurring as a primary response to the emergence of cytosolic Aβ oligomers, could contribute to 
a key catalyzing mechanism of subsequent aberrant synaptic transmission. This finding therefore high-
lights a surprising discrepancy in our current understanding of the effects of Aβ on synaptic receptors. 
Whereas previous studies have shown that Aβ can drive the downregulation of synaptic transmission, in 
some cases mediated by the internalization of AMPARs and NMDARs42–45, our findings and those of oth-
ers seem to indicate, in contrast, that Aβ can actually facilitate synaptic transmission, possibly through 
inducing the expression of receptors46–49. Presumably this is due to different time courses of Aβ -mediated 
toxic effects (the above studies, for example, range in treatment times from minutes to hours) and/or 
CP-AMPARs mediated secondary toxic insults50,51.
The mechanisms regulating the trafficking of GluA1-containing AMPARs have previously been char-
acterised, and generally converge on C-terminus phosphorylation events52–54. One canonical mechanism 
is the phosphorylation of the s845 residue on GluA1, priming its expression at the synapse52. Our find-
ing that the expression of S845A, a mutant form of GluA1 which cannot be phosphorylated at s845, 
blocks the Aβ -induced enhancement of EPSCA, suggests that Aβ operates this rapid effect via a regulated 
physiological mechanism; the PKA-mediated phosphorylation of GluA1-s845. CaMKII has previously 
been implicated in AMPAR regulation34,35. Consistent with this role, we found that inhibiting CaMKII 
blocks the Aβ -induced enhancement of EPSCA. Interestingly, we observed a delayed effect under these 
conditions; whilst there was an initial increase in EPSCA, this rapidly declined. This might be explained 
by previously reported roles for CaMKII in the synaptic stabilization of AMPARs55. Therefore, PKA 
and CaMKII may act in concert in this mechanism, promoting the expression and then stabilization 
of synaptic AMPARs, respectively. Together, these data raise the interesting question as to whether Aβ 
might actually operate physiologically to regulate synaptic glutamate receptor expression, and whether its 
aberrant cytosolic presence leads to a dysregulated physiological process. Clearly, more work is required 
to further understand a possible non-pathological role of Aβ .
CP-AMPARs are expressed at an early postnatal age and are replaced with GluA2-containing 
Ca2+ -impermeable AMPARs during development56–58. CP-AMPARs are critically involved in physi-
ological34,59,60 and pathological plasticity in the matured synapse61–63. Furthermore, growing evidence 
suggests CP-AMPARs prime neurodegenerative diseases including stroke, ischaemia and amyotrophic 
lateral sclerosis62,64. We found that blocking CP-AMPARs prior to exposure to exogenous Aβ prevented 
the facilitation of synaptic transmission. Therefore, our findings support the hypothesis that progressive 
Aβ -mediated CP-AMPAR expression is a pivotal catalyst for the onset of pathology.
The early accumulation of intracellular Aβ has been shown to be neurotoxic65 and transgenic models 
have shown it to be sufficient for cognitive impairments prior to the increase in extracellular Aβ 21,66. 
Indeed, the accumulation of intracellular Aβ has previously been shown to be prevalent in the brains 
of AD patients67–69, and this is thought to be one of the earliest events in the pathology, preceding Aβ 
plaques and neurofibrillary tangles67,70. A recent report has shown that the infusion and accumulation 
of Aβ into neurons can have significant impairing effects on synaptic function71. Accounting for these 
findings and our data, the accumulation of intracellular Aβ will likely prove to be a catalyzing event 
in the pathogenesis of the disease. Given that the primary response to an increase in intracellular Aβ 
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Figure 5. Exogenous application of Aβ induces GluA1 surface expression. (a) Aβ treatment caused an 
increase in the surface expression of GluA1, but not GluA2/3 as shown through a biotinylation assay. (b) 
Exogenous application of Aβ caused an increase in EPSCA (n = 6), (c) which was prevented when slices were 
perfused with IEM (n = 6).
www.nature.com/scientificreports/
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appears to be the expression of CP-AMPARs at the synapse, targeting CP-AMPARs may provide a means 
of restoring synaptic function in AD.
Methods
Amyloid-β preparation. The amyloid-β 1-42 peptide (Aβ ; Millipore, UK) was first dissolved at a 
concentration of 1 mg / ml in 100% HFIP (1,1,1,3,3,3-hexafluoro-2-propanol [Sigma-Aldrich]). This 
solution was incubated at room temperature for 1 h with occasional vortexing. Next, the solution was 
sonicated for 10 min in a water bath sonicator. The solution was then dried under a gentle stream of 
nitrogen gas. 100% DMSO was then used to resuspend the peptide, which was then incubated at room 
temperature for 12 min with occasional vortexing. This solution was finally aliquoted into smaller vol-
umes and stored at –80 °C. For a working solution, D-PBS (Invitrogen, UK) was added to the peptide 
stock solution and incubated for 2 h at room temperature to allow for peptide aggregation. To prepare 
monomeric Aβ , the same proceedure outlined above was followed, with the exception of the 2 h room 
temperature aggregation step.
Electrophysiology. All animal experiments were carried out in accordance with the UK Scientific 
Procedures Act, 1986 and associated guidelines. The methods were carried out in accordance with the 
approved guidelines. All experimental protocols were approved by the University of Bristol Animal 
Welfare & Ethical Review Body. Acute hippocampal slices were prepared from 26 - to 32 - day-old male 
Wistar rats. Animals were sacrificed by dislocation of the neck and then decapitated. The brain was 
rapidly removed and placed in ice-cold artificial CSF (aCSF) containing (in mM): 124 NaCl, 3 KCl, 26 
NaHCO3, 1.25 NaH2PO4, 2 CaCl2, 1 MgSO4, 10 D-glucose, and 0.1 picrotoxin (bubbled with 95% O2 / 
5% CO2). Transverse hippocampal slices (400 μ m thick) were prepared using a McIllwain tissue chop-
per (Mickle Laboratory Engineering Co. Ltd., Gomshall, UK). Hippocampal slices were stored in aCSF 
(20–25 °C) for 1–2 h before transferring to the recording chamber, in which they were submerged in 
aCSF (~30 °C) flowing at 2 ml / min. Stimulating electrodes were placed in the CA2 (Schaffer Collateral 
pathway). Single stimuli (constant voltage) were delivered to the Schaffer Collateral input at 30 sec inter-
vals (0.016 Hz).
For whole-cell recordings, recording pipette (4–6 MΩ ) solutions (280 mOsm [pH 7.2]) comprised 
(mM) CsMeSO4, 130; NaCl, 8; Mg-ATP, 4; Na-GTP, 0.3; EGTA, 0.5; HEPES 10; QX-314, 6. CA1 neu-
rons were voltage clamped at − 70 mV. Recordings were carried out using a MultiClamp 700B amplifier 
(Axon Instruments, Foster City, CA). EPSC amplitude, series resistance, input resistance, and DC were 
monitored and analyzed online and offline using the WinLTP software (http://www.ltp-program.com). 
Only cells with series resistance < 25 MΩ with a change in series resistance < 10% from the start were 
included in this study. The amplitude of the excitatory postsynaptic currents (EPSCs) was measured and 
expressed relative the normalized baseline (first 5 min of recording).
Hippocampal Slice Culture and Whole-Cell Patch Recording. Organotypic hippocampal slice 
cultures were prepared from 6–8 days old Wistar rats. Rats were decapitated and brains were rapidly 
removed and placed in cold cutting solution that contained (mM) sucrose, 238; KCl, 2.5; NaHCO3, 
26; NaH2PO4, 1; D-glucose, 11; MgCl2, 5 and CaCl2, 1. Hippocampal slices (350 μ m) were cut using a 
McIlwain tissue chopper, and cultured on semi-permeable membrane inserts (Millipore Corporation, 
Bedford, MA, USA) in a six-well plate containing culture medium (78.8% minimum essential medium, 
20% heat-inactivated horse serum, 30 mM HEPES, 26 mM D-glucose, 5.8 mM NaHCO3, 2 mM CaCl2, 
2 mM MgSO4, 70 μ M Ascorbic Acid, 0.1% 1 mg / ml Insulin, pH adjusted to 7.3 and 320–330 mOsm). 
Slices were cultured for 7 – 9 days in vitro (DIV) with a change of medium every 2 days, without anti-
biotics. Neurons were transfected using a biolistic gene gun (Helios Gene-gun system, Bio Rad, U.S.A.) 
at DIV 3–4 (100 μ g DNA; 90% of the construct to test; 10% pEGFP-C1). Electrophysiological recordings 
were performed at 3–4 days after transfection. Recordings were carried out in solution containing (mM) 
NaCl, 119; KCl, 2.5; NaHCO3, 26; NaH2PO4, 1; D-glucose, 11; CaCl2, 4; MgCl2, 4; picrotoxin, 0.02; 
2-chloroadenosine,0.01 and gassed with 5% CO2 / 95% O2.
GluA1 shRNA. The following complementary oligonucleotide sequences were annealed 
and ligated into the EcoRI / ApaI sites of the pSilencer v1.0 vector (Ambicom): (Forward) 
5’-GAACTGGCAGGTAACGGCTTTCAAGAGAAGCCGTTACCTGCCAGTTCTTTTTT-3’ 
and (Reverse) 5’-AATTAAAAAAGAACTGGCAGGTAACGGCTTCTCTTGAA AGCCGTTACCTGCCA 
GTTCGGCC-3’. The plasmid was then amplified in DH5α competent cells and the purified DNA was 
qualitatively analysed and sequenced to determine satisfactory plasmid ligation.
GluA2 shRNA. The following complementary oligonucleotide sequences were annealed and ligated 
into the EcoRI / ApaI sites of the pSilencer v1.0 vector (Ambicom): (Forward) 5’-CCATCGAAAGTGCT 
GAGGATTCAAGAGATCCTCAGCACT TTCGATGGAATTT TTT-3’ and (Reverse) 5’-AATTAAAAAA 
TTCCATCGAAAGTGCTGAGGATCTCTTGAATCCTCAGCACTTTCGATGGGCC-3’.  The plasmid was 
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then amplified in DH5α competent cells and the purified DNA was qualitatively analysed and sequenced 
to determine satisfactory plasmid ligation.
GluA1 S845 mutant. The GluA1 S845A construct was a generous gift from Jeff Bernhardt. Briefly, 
site-directed mutagenesis was performed with Chameleon (Stratagene) on the pRK5_GluA1i construct 
mutating serine 845 residue to alanine.
Slice biotinylation and NeutraAvidin pull-down. Surface biotinylation of acute slices was per-
formed as described previously with some modifications72. Briefly, slices were initially washed twice in 
aCSF and subsequently incubated in aCSF containing 1 mg / ml Sulfo-NHS-SS-Biotin (Thermo Scientific, 
Rockford, USA) for 45 min at 4 °C to allow for labelling of all surface membrane proteins. Excess biotin 
was removed by washes in aCSF containing NH4Cl. Tissue was then homogenised in lysis buffer contain-
ing 25 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 10m 
M NaF and a cocktail of protease inhibitors (Sigma, St Louis, USA) and incubated for 30 min prior to 
centrifugation at 1,000 g to remove cellular debris. The total protein concentration was determined using 
the Pierce BCA kit. Subsequently, 100 μ l of StreptaAvidin beads (Upstate, USA) were added to 500 μ g 
of protein lysate and placed on a rotator at 4 °C for 2 hr. Samples were then washed five times in lysis 
buffer; beads were pulled-down after each wash by gentle centrifugation. Bound proteins were eluted by 
adding 2 X SDS reducing buffer and moderate heating at 60 °C for 30 min. The resulting supernatant was 
transferred to new tubes and heated at 90 °C for 5 min prior to gel loading.
Statistical Analyses. Data were analyzed from one slice per rat (i.e., n = number of slices = number 
of rats). Data pooled across slices are expressed as the mean ± s.e.m. Significance (p < 0.05) was tested 
using two-tailed t-tests. For electrophysiology experiments, mean ± s.e.m. data from the 40 min time-
point are described.
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